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AngiotensinII(AngII)isinvolvedinnotonlytheformationofcardiachypertrophybutalsothedevelopmentofcardiacremodeling
both of which are associated with myocardial angiogenesis. This study was therefore performed to clarify the eﬀects of AngII on
the formation of vasculatures by cultured cardiac microvascular endothelial cells (CMVECs) after a long-period stimulation with
orwithouttheAngIIpreconditioning. Incubation withAngIIfor18hrssigniﬁcantlyimpairedtheformationofcapillary-like tubes
comparing to that without AngII. CMVECs with AngII pretreatment for 5 and 10min formed more capillary-like tubes than those
withoutAngIIpretreatment,suggestingthatpreconditioningwithAngIIatalowerdoseforashortperiodcouldpreventthefurther
damage of CMVECs by a higher concentration of AngII. Moreover, AngII (10
−7 M) stimulation for 5 and 10min signiﬁcantly
induced the increase in extracellular signal-regulated protein kinases (ERKs) phosphorylation, and an ERKs inhibitor, PD98059,
abrogated the increase in the formation of capillary-like tubes induced by the AngII-pretreatment. In conclusion, preconditioning
with a lower concentration of AngII for a short period prevents the subsequent impairment of CMVECs by a higher dose of AngII,
at least in part, through the increase in ERKs phosphorylation.
1.Introduction
Cardiac hypertrophy usually occurs as an adaptive response
to increased workload to maintain cardiac function in
early stages [1]. However, prolonged cardiac hypertrophy
can lead to heart failure lately [2]. It has been postulated
that a mismatch between the number of capillaries and
the size of cardiomyocytes occurs during the development
of cardiac hypertrophy and causes myocardial hypoxia [3,
4]. Various studies indicate that a potential relationship
exists among cardiac angiogenesis, cardiac hypertrophy, and
cardiac function [5–7]. Furthermore, rennin-angiotensin
systems (RASs), especially angiotensinII(AngII), play a cru-
cial role in the development of cardiac hypertrophy [8, 9].
AngII is proved to be related with myocardial cell apoptosis
and remodeling [10–12]. Though both dysfunctions of
angiogenesis in myocardium and AngII are critical to the
progress of cardiac hypertrophy and heart failure [13], roles
of AngII in myocardial angiogenesis at the diﬀerent stages
during the pathogenic process are unclear. The aim of this
study was to identify eﬀects of AngII on the formation of
vasculatures by cultured cardiac microvascular endothelial
cells (CMVECs) at an early or later time point after stim-
ulation.
2.MaterialsandMethods
2.1. Cell Culture and AngiotensinII Treatment. Primary rat
cardiac microvascular endothelial cells (CMVECs) were
obtained from male Wistar rats (8-9 weeks old) by the
method of planting myocardial tissue [14, 15]a n dw e r ec u l -
tured in high-glucose Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (Gibco, USA) containing 20% fetal bovine serum
(FBS, Hyclone), 100u/mL penicillin, and 100u/mL strepto-
mycin (Sigma, USA). The 2nd and 3rd rat CMVECs were
seeded on a 6-well plate at 5 × 105/well and cultured for2 Journal of Biomedicine and Biotechnology
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Figure 1: Time-dependent eﬀects of AngII preconditioning on AngII-induced impairment of capillary-like tube formation in cultured
CMVECs. CMVECs were pretreated with AngII (10−7M) for the indicated times and then seeded onto the matrigel in plates containing
AngII (10−6M) or not (control). Eighteen hrs later, the formation of capillary-like tubes was observed under an optical microscope. (a)
Representative photomicrographs of capillary-like tubes (100xmagniﬁcation). (b) Quantitative analysis for capillary-like tube formation.
Capillary-like tubes were counted in randomly selected 5 ﬁelds for each plate. Data represent mean ± SD obtained from 15 independent
experiments (n = 15);
∗P < 0.05 versus control group; #P < 0.05 versus the group without AngII pretreatment (0min).
24 hours. And 24 hours later, cells were cultured in serum-
free DMEM for another 24 hours and then were incubated
by AngII (10−7M) for 5, 10, 15, 30, and 60min, respectively.
Finally, CMVECs were collected and lysed for the further
western blotting analysis and capillary-like tube formation
analysis.
2.2. PD98059 Treatment. The 2nd and 3rd CMVECs were
seeded on a 6-well plate at 5 × 105/well and cultured for 24
hours. Then, they were cultured in serum-free DMEM for
another 24 hours, incubated by PD98059 (50μM) for 30min
(DMSOascontrols)andAngII(10−7M)forafurther10min.
Finally, cells were collected and lysed for the further western
blotting analysis and capillary-like tube formation analysis
2.3. Western Blotting Analysis. T o t a lp r o t e i nw a se x t r a c t e d
from the cultured cells and then electrophoresed in 12%
polyacrylamide gel and transferred to PVDF membrane. The
expression of extracellular signal-regulated protein kinases
(ERKs) phosphorylation was detected using a Phospho-
p44/42 MAPK Rabbit mAb (1:1,000; Cell Signaling). The
membrane was then incubated with peroxidase-conjugated
rabbitanti-goatIgG(1:5,000;Jackson)andHRP-conjugated
monoclonal mouse antiglyceraldehyde-3-phosphate dehy-
drogenase (GAPDH, KangChen, China). Immunoreactive
proteins were subjected to an ECL detection system (GE
healthcare, RPN2106).
2.4. Capillary-Like Tube Formation. 200μL growth-factor-
reduced matrigel matrix (BD company) was homogenized
and layered into a 24-well plate on a cooled planar surface
and allowed to solidify at 37◦C. CMVECs that AngII
(10−7M) pretreated or PD98059 pretreated were detached
with trypsin EDTA, resuspended in high-glucose DMEM,
and supplemented with 1% of FBS and AngII (10−6M). And
suspension was seeded into plates at 5 × 104 cells/well and
cultivated at 37◦Ca t m o s p h e r ew i t h5 %C O 2/95% air for
18hours. Images of tubes were taken at 100xmagniﬁcation
with a digital output camera attached to an inverted phase-
contrast microscope (Leica. Germany), and ﬁve random
ﬁelds of view were counted to analyze the relative number
of capillary-like tubes.
2.5. Statistical Analysis. All the data were presented as mean
± SD and were analyzed using ANOVA tests (least signiﬁcantJournal of Biomedicine and Biotechnology 3
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Figure 2: Time-dependent eﬀects of AngII on ERKs phosphorylation in cultured CMVECs. CMVECs were treated with AngII (10−7M)
for the indicated times and then collected and lysed for western blot analysis. (a) Representative immunoblots showing the expression of
phosphor ERKs. GAPDH was used as a loading control. (b) Quantitative analysis for the expression of phosphor ERKs. Data represent mean
± SD obtained from 6 independent experiments (n = 6);
∗P < 0.05 versus control group (0min).
diﬀerence t-tests) for multiple-means comparison. A two-
tailedP valueof<0.05wasconsideredstatisticallysigniﬁcant.
All statistical analysis was performed by SPSS 16.0 for
Windows (SPSS Inc., Chicago, IL).
3. Results
3.1. Impairment of CMVECs to Form Capillary-Like Tubes
and the Protective Eﬀect of AngII Pretreatment. In order to
investigatetheeﬀectofAngIIonCMVECscapillary-liketube
formation, we select the function of its capillary-like tube
formation to observe. The results showed that stimulation
of cultured CMVECs with AngII (10−6M )f o r1 8h o u r s
impaired its capillary-like tube formation, and cells that
either AngII (10−7M) pretreated for 5 or 10min formed
more capillary-like tubes than those without AngII pretreat-
ment (Figures 1(a) and 1(b)), suggesting that precondition
with AngII at a lower dose for a short period could prevent
the subsequent impairment of CMVECs by a higher dose of
AngII.
3.2. Phosphorylation of ERKs in Cultured CMVECs following
AngII Stimulation. In order to identify the eﬀect of AngII
on ERKs phosphorylation in CMVECs, we observed levels
of ERKs phosphorylation using western blotting analysis.
The ﬁgures showed that ERKs phosphorylation in CMVECs
under AngII (10−7M) stimulation for 5 and 10min was sig-
niﬁcantly increased more than those without AngII addition
(Figures 2(a) and 2(b)).
3.3. ERKs Phosphorylation Participated in the Protective Eﬀect
by Preconditioning. The above results pointed out that pre-
treatedCMVECswithAngIIfor5or10mincouldprotectthe
subsequent impairment induced by a higher dose of AngII
(Figure 1), and interestingly, levels of ERKs phosphorylation
raisedatthatstimulationpointasFigure 2reveals.Therefore,
we hypothesized that ERKs phosphorylation might take
part in the protective eﬀect by preconditioning. PD98059,
an ERKs inhibitor, was selected to inhibit ERKs phos-
phorylation, and function of capillary-like tube formation
was observed in CMVECs. Results indicated that 50μM
PD98059 could inhibit ERKs phosphorylation to the last
penny (Figures 3(a) and 3(b)), and the number of capillary-
like tubes of CMVECs signiﬁcantly decreased when inhibited
ERKs phosphorylation (Figures 4(a) and 4(b)). The ﬁgures
suggestedthatpreconditioningwithalowerconcentrationof
AngIIforashortperiodpreventsthesubsequentimpairment
of CMVECs by a higher dose of AngII through the increase
of ERKs phosphorylation.4 Journal of Biomedicine and Biotechnology
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Figure 3: The eﬀects of PD98059 on ERKs phosphorylation in cultured CMVECs. CMVECs were incubated with (+) or without (−)
PD98059 (50μM), an ERKs inhibitor, for 30min and then treated with (+) or without (−) AngII (10−7M) for 10min. Thereafter, the cells
were collected and lysed for western blotting. (a) Representative immunoblots showing the expression of phosphor ERKs. GAPDH was used
as a loading control. (b) Quantitative analysis for the expression of phosphor ERKs. Data represent mean ± SD obtained from 4 independent
experiments (n = 4). ∗P<0.05 versus CMVECs with neither PD98059 nor AngII treatment; #P < 0.05 versus CMVECs without PD98059
but with AngII treatment.
4. Discussion
In normal mammalian myocardium, each cardiomyocyte is
surrounded by an intricate network of capillaries and is next
to cardiac microvascular endothelial cells (CMVECs) [16].
The unique structure between CMVECs and cardiomyocyte
determines that CMVECs may participate in regulating
cardiomyocyte function. In mature myocardium, CMVECs
not only supply cardiomyocytes with oxygen and nutrient
but also promote cardiomyocytes organization and survival
with local protective signals. Cardiomyocytes cocultured
with CMVECs may promote marked cardiomyocyte reorga-
nization along the EC structures and inhibit cardiomyocytes
apoptosis and necrosis [17, 18]. So, CMVECs are very
important in the heart. A reduction of capillary length
density has been found in several experimental models
of cardiac hypertrophy [19]. In particular, major roles
were shown for VEGF, angiopoietin, and Tie2 in cardiac
vasculogenesis and angiogenesis after AngII infusion [20]. In
the present study, our data provides that AngII incubated for
18 hours could damage functions of CMVECs capillary-like
tube formation, AngII (10-7M) pretreatment for 5∼10min
could diminish the subsequent impairment induced by a
higher dose of AngII incubation. And the eﬀect was related
to ERKs phosphorylation which was considered to be one
signalrelatedtocellproliferation.Sincethesimilarprotective
eﬀect of AngII by preconditioning in ischemia-reperfusion
models had been approved [21–29], we did not observe
the preconditioning eﬀect in perfusion heart here. Though
the detailed mechanisms underlying ERKs phosphorylation
in function of capillary-tube formations and other various
pathological angiogenesis remain to be fully investigated,
and the active preconditioning eﬀect might be diﬃcult to
be realized in organism, our data had unraveled that this
important molecular ERKs phosphorylation maintaining
proliferation participated in the process of protection for
CMVECs to form capillary-like tubes. Since AngII -induced
angiogenesis is a critical physiological or pathological event
in diverse cardiac diseases, these ﬁndings might be broadly
applicable and signiﬁcant in the therapeutics of cardiac
diseases such as hypertension, acute myocardial infarction,
and chronic systolic heart failure, particularly as how to
explain that ACEI/ARB combination therapy was associated
with more adverse eﬀects without any increase in beneﬁt. InJournal of Biomedicine and Biotechnology 5
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Figure 4: Eﬀects of ERKs inhibition on AngII preconditioning-induced improvement of vasculature formation under the condition of
AngII stimulation. CMVECs preincubated with or without PD98059 (50μM) for 30min were treated with 10−7M AngII for the indicated
times, and then the cells were seeded onto the matrigel in plates containing AngII (10−6M) or not (control). Eighteen hrs later, the
formation of capillary-like tubes was observed under an optical microscope. (a) Representative photomicrographs of capillary-like tubes
(100xmagniﬁcation). (b) Quantitative analysis for capillary-like tube formation. Capillary-like tubes were counted in randomly selected 5
ﬁelds for each plate. Data represent mean ± SD obtained from 12 independent experiments (n = 12).
∗P < 0.05 versus control group;
#P < 0.05 versus the group without AngII pretreatment (0min); P < 0.05 versus the group pretreated with AngII (10min) but without
PD98059.
other words, that appropriate inhibition of AngII rather than
complete inhibition of AngII is beneﬁt of cardiac diseases.
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